Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vivo (non-LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2004-03-01 to 2001-04-01
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: comparable to guideline study with acceptable restrictions

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2004

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 406 (Skin Sensitisation)
Version / remarks:
1992
Deviations:
yes
Remarks:
no positive control
GLP compliance:
not specified
Type of study:
guinea pig maximisation test
Justification for non-LLNA method:
The tesing is finished before the REACH regulation came into force.

Test material

Constituent 1
Chemical structure
Reference substance name:
N-[3-(dimethylamino)propyl]docosanamide
EC Number:
262-134-8
EC Name:
N-[3-(dimethylamino)propyl]docosanamide
Cas Number:
60270-33-9
Molecular formula:
C27H56N2O
IUPAC Name:
N-[3-(dimethylamino)propyl]docosanamide
Test material form:
solid
Details on test material:
- Name of test material: DIMAPDO lactate
- Molecular weight: 514.83 g/mol
- Analytical purity: 99.2 %
- Physical state: solid

In vivo test system

Test animals

Species:
guinea pig
Strain:
Hartley
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Age at study initiation: 5 weeks
- Weight at study initiation: 336 g (mean at induction)
- Housing: in groups of 5 animals in aluminum cages (W350 x D400 x H230: Natsume Seisakusho Co., Ltd.)
- Diet (e.g. ad libitum): solid food (RC4: Oriental Yeast Co., Ltd.), ad libitum
- Water (e.g. ad libitum): filtered tap water, ad libitum
- Acclimation period: 6 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 ± 2°C
- Humidity (%): 50 ± 10%
- Air changes (per hr): 17
- Photoperiod (hrs dark / hrs light): 12/12

Study design: in vivo (non-LLNA)

Induction
Route:
intradermal and epicutaneous
Vehicle:
other: for intradermal induction: physiological saline; for epicutaneous induction and challenge 50% ethanol in water
Concentration / amount:
intradermal induction: 0.01%
epicutaneous induction: 30%
challenge: 0.5%, 1%, 3%, 5%, 10%, 30%

Concentration selection based on a preliminary dose range finding study.
Challenge
Route:
epicutaneous, occlusive
Vehicle:
other: for intradermal induction: physiological saline; for epicutaneous induction and challenge 50% ethanol in water
Concentration / amount:
intradermal induction: 0.01%
epicutaneous induction: 30%
challenge: 0.5%, 1%, 3%, 5%, 10%, 30%

Concentration selection based on a preliminary dose range finding study.
No. of animals per dose:
8 (preliminary study); 10 (test group); 5 (control group)
Details on study design:
RANGE FINDING TESTS:
pilot experiment with 8 animals to determine which concentration of the test substance
- led to slight irritation after intradermal application (determination of the maximum compatible dose); concentrations tested: 0.01%, 0.03%, 0.05%, 0.1%, 0.5%, 1% and 5% (w/w)
- led to slight irritation after dermal application; concentrations tested: 0.3%, 0.5%, 1%, 3%, 5% and 10% (w/w)

MAIN STUDY
A. INDUCTION EXPOSURE
Intradermal induction (day 0)
- No. of exposure sites: 2
- Test groups: test substance
- Control group: vehicle
- Site: left and right back
- Frequency of applications: 1
- Concentrations:
0.1 mL FCA (mixed at a ratio of 1+1 in vehicle)
0.1 mL 0.01% test substance (or physiological saline in control)
0.1 mL 0.02% test substance (or physiological saline in control) + FCA (mixed at a ratio of 1+1 in vehicle)

Epicutaneous induction (day 8)
- No. of exposures: 1
- Exposure period: 48 h
- Test groups: test substance
- Control group: vehicle
- Site: back, same region as for intradermal induction
- Frequency of applications: 1
- Concentrations: 30% test substance (or 50% ethanol in water in control)
- Since the test substance is non-irritating, 0.5 g of 10% SDS (vaseline base) was applied on day 7

B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 21
- Exposure period: 24 h
- Test groups: 0.05 mL of the test substance soaked in the cloth portion of an adhesive plaster for patch test
- Control group: same as test group
- Site: lateral abdomen
- Concentrations: 0.5%, 1%, 3%, 5%, 10%, 30% test substance (w/w)
- Evaluation (hr after challenge): 3h, 24 h, 48 h
Challenge controls:
yes, vehicle only during induction phase
Positive control substance(s):
no

Results and discussion

In vivo (non-LLNA)

Resultsopen allclose all
Reading:
1st reading
Hours after challenge:
24
Group:
test chemical
Dose level:
0.5%, 1%, 3%, 5%, 10%, 30%
No. with + reactions:
0
Total no. in group:
10
Clinical observations:
no
Remarks on result:
other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 0.5%, 1%, 3%, 5%, 10%, 30%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No.
Reading:
2nd reading
Hours after challenge:
48
Group:
test chemical
Dose level:
0.5%, 1%, 3%, 5%, 10%, 30%
No. with + reactions:
0
Total no. in group:
10
Clinical observations:
no
Remarks on result:
other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0.5%, 1%, 3%, 5%, 10%, 30%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No.
Reading:
1st reading
Hours after challenge:
24
Group:
negative control
Dose level:
0.5%, 1%, 3%, 5%, 10%, 30%
No. with + reactions:
0
Total no. in group:
5
Clinical observations:
no
Remarks on result:
other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 0.5%, 1%, 3%, 5%, 10%, 30%. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: No.
Reading:
2nd reading
Hours after challenge:
48
Group:
negative control
Dose level:
0.5%, 1%, 3%, 5%, 10%, 30%
No. with + reactions:
0
Total no. in group:
5
Clinical observations:
no
Remarks on result:
other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0.5%, 1%, 3%, 5%, 10%, 30%. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: No.

Any other information on results incl. tables

Reading Hours after challenge Group Dose level No. with + reactions Total no. in group Clinical observations
Additional reading 3 test group 0.5%, 1%, 3%, 5%, 10%, 30% 0 10 No
Additional reading 3 negative control 0.5%, 1%, 3%, 5%, 10%, 30% 0 5 No

No abnormality in the general conditions was observed after induction or challenge during the study period and the animals showed satisfactory body weight increases.

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
not sensitising
Migrated information Criteria used for interpretation of results: other: CLP, EU GHS (Regulation (EC) No. 1272/2008)
DIMAPDO lactate is not a dermal sensitizer in this Guinea pig maximisation test.
Executive summary:

In a dermal sensitization study with DIMAPDO lactate 23 young female Albino Hartley guinea pigs (8 preliminary study, 10 in test group, 5 in control group) were tested using the method of Guinea pig maximization test equivalent to OECD Guideline 406 (1992). No positive control was reported.

Concentration selection was based on a preliminary dose range finding study:

intradermal induction: 0.01% in physiological saline

epicutaneous induction: 30% in 50% ethanol in water

challenge: 0.5%, 1%, 3%, 5%, 10%, 30% in 50% ethanol in water

One day prior to epicutaneous induction the sites were pretreated with SDS to create local skin irritation.

There were no signs of erythema or oedema in any dose group 3, 24 and 48 hours after patch removal. Therefore, DIMAPDO lactateis not a dermal sensitizer in this study.